Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib Plus Binimetinib in BRAF V600 Mutated Relapsed/Refractory HCL
NCT04324112Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2020
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of encorafenib, binimetinib in hairy cell leukemia (HCL), sponsored by National Cancer Institute. Started Oct 2020; status: active, not recruiting.
02
Drugs
encorafenibbinimetinib
03
Conditions
hairy cell leukemia (HCL)
Beyond the preview
Go deeper on NCT04324112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04324112.